Increased bax expression is associated with cell death induced by ganciclovir in a herpes thymidine kinase gene-expressing glioma cell line

Human Gene Therapy

Volumn 10, Issue 4, 1999, Pages 679-688

  Craperi, D ^a   Vicat, J M ^a   Nissou, M F ^a   Mathieu, J ^b   Baudier, J ^c   Benabid, A L ^a   Verna, J M ^a  

^a INSERM   (France)

^b CENTRE DE RECHERCHES   (France)

^c CEA GRENOBLE   (France)

Author keywords

[No Author keywords available]

Indexed keywords

GANCICLOVIR; GUANOSINE; PROTEIN BAX; PROTEIN BCL X; PROTEIN P53; THYMIDINE KINASE;

ANIMAL CELL; APOPTOSIS; ARTICLE; CELL CYCLE S PHASE; CELL DEATH; CELL SURVIVAL; CELL ULTRASTRUCTURE; CONTROLLED STUDY; CYTOTOXICITY; GENE EXPRESSION; GENE THERAPY; GENETIC TRANSFECTION; GLIOMA CELL; HERPES VIRUS; MICROSCOPY; MITOSIS INHIBITION; NONHUMAN; RAT; VIRUS RECOMBINANT;

ANIMALS; ANTIVIRAL AGENTS; BCL-2-ASSOCIATED X PROTEIN; CELL DEATH; CELL DIVISION; GANCICLOVIR; GLIOMA; PROTO-ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS C-BCL-2; RATS; SIMPLEXVIRUS; THYMIDINE KINASE; TRANSFECTION; TUMOR CELLS, CULTURED; TUMOR SUPPRESSOR PROTEIN P53;

ANIMALIA; HERPES; HERPESVIRIDAE; RNA VIRUSES; SIMPLEXVIRUS;

EID: 0033105565     PISSN: 10430342     EISSN: None     Source Type: Journal    
DOI: 10.1089/10430349950018751     Document Type: Article

References (55)

1. ANKARCRONA, M., DYPBUKT, J.M., BONFOCO, E., ZHIVOTOVSKY, B., ORRENIUS, S., LIPTON, S.A., and NICOTERA, P. (1995). Glutamate-induced neuronal death: A succession of necrosis or apoptosis depending on mitochondrial function. Neuron 15, 961-973.
2. ASAI, A., MIYAGI, Y., SUGIYAMA, A., GAMANUMA, M., HONG, S.I., TAKAMOTO, S., NOMURA, K., MATSUTANI, M., TAKAKURA, K., and KUCHINO, Y. (1994). Negative effects of wild-type p53 and s-Myc on cellular growth and tumorigenicity of glioma cells. J. Neuro-Oncol. 19, 259-268.
3. BARBA, D., HARDIN, J., RAY, J., and GAGE, F.H. (1993). Thymidine kinase-mediated killing of rat brain tumors. J. Neurosurg. 79, 729-735.
4. BARBA, D., HARDIN, J., SADELAIN, M., and GAGE, F.H. (1994). Development of anti-tumor immunity following thymidine kinase-mediated killing of experimental brain tumors. Proc. Natl. Acad. Sci. U.S.A. 91, 4348-1352.
5. BECK, C., CAYEUX, S., LUPTON, S.D., DORKEN, B., and BLANKENSTEIN, T. (1995). Thy thymidine kinase/ganciclovir-mediated "suicide" effect is variable in different tumor cells. Hum. Gene Ther. 6, 1525-1530.
6. BI, W.L., PARISEK, L.M., WARNICK, R., and STAMBROOK, P.J. (1993). In vitro evidence that metabolic cooperation is responsible for the bystander effect observed with HSV-TK retroviral gene therapy. Hum. Gene Ther. 4, 725-731.
7. BOTVIATSIS, E.J., PARK, J.S., SENA-ESTEVES, M., KRAMM, C.M., CHASE, M., EFIRD, J.T., WEI, M.X., BREAKEFIELD, X.O., and CHIOCCA, E.A. (1994). Long-term survival of rats harboring brain neoplasms treated with ganciclovir and a herpes simplex virus vector that retains an intact thymidine kinase gene. Cancer Res. 54, 5745-5751.
8. CAELLES, C., HELMBERG, A., and KARIN M. (1994). p53-dependent apoptosis in the absence of transcriptional activation of p53-target genes. Nature (London) 370, 220-223.
9. CARUSO, M., PANIS, Y., GAGANDEEP, S., HOUSSIN, D., SALZMANN, J.L., and KLATZMANN, D. (1993). Regression of established macroscopic liver metastases after in situ transduction of a suicide gene. Proc. Natl. Acad. Sci. U.S.A. 90, 7024-7028.
10. CHEN, C., SHINE, H.D., GOODMAN, J.C., GROSSMAN, R.G., and WOO, S.L.C. (1994). Gene therapy for brain tumors: Regression of experimental gliomas and adenovirus-mediated gene transfer in vivo. Proc. Natl. Acad. Sci. U.S.A. 91, 3054-3057.
11. CHERNOVA, O.B., CHERNOV, M.V., AGARWAL, M.L., TAYLOR, W.R., and STARK, G.R. (1995). The role of p53 in regulating genomic stability when DNA and RNA synthesis are inhibited. Trends Biochem. Sci. 20, 431-434.
12. COLOMBO, M., BENEDETTI, S., OTTOLENGHI, S., MORA, M., POLLO, B., POLI, G., and FINOCCHARIO, G. (1995). The "by-stander effect": Association of U-87 cell death with ganciclovir-mediated apoptosis of nearby cells and lack of effect in athymic mice. Hum. Gene Ther. 6, 763-772.
13. COOL, V., PIROTTE, B., GERARD, C., DARGENT, J.-L., BAUDSON, N., LEVIVIER, M., GOLDMAN, S., HILDEBRAND, J., BROTCHI, J., and VELU, T. (1996). Curative potential of herpes simplex virus thymidine kinase gene transfer in rats with 9L gliosarcoma. Hum. Gene Ther. 7, 627-635.
14. CULVER, K.W., RAM, Z., WALLBRIDGE, S., ISHII, H., OLDFIELD, E.H., and BLAESE, R.M. (1992). In vivo gene transfer with retroviral vector-producer cells for treatment of experimental brain tumor. Science 256, 1550-1552.
15. DARZYNKIEWICZ, Z. (1995). Apoptosis in antitumor strategies: Modulation of cell cycle or differentiation. J. Cell. Biochem. 58, 151-159.
16. DATTA, R., MANOME, Y., TANEJA, N., BOISE, L.H., WEICHSELBAUM, R., THOMPSON, C.B., SLAPAK, C.A., and KUFE, D. (1995). Overexpression of Bcl-xL by cytotoxic drug exposure confers resistance to ionizing radiation-induced internucleosomal DNA fragmentation. Cell Growth Differ. 6, 363-370.
17. ELSHAMI, A.A., SAAVEDRA, A., ZHANG, H., KUCHARCZUK, J.C., SPRAY, D.C., FISHMAN, G.I., AMIN, K.M., KAISER, L.R., and ALBELDA, S.M. (1996). Gap junctions play a role in the by-stander effect of the herpes simplex virus thymidine kinase/ganciclovir system in vitro. Gene Ther. 3, 85-92.
18. EZZEDDINE, Z.D., MARTUZA, R.L., PLATIKA, D., SHORT, M.P., MALIK, A., CHOI, B., and BREAKEFIELD, X.O. (1991). Selective killing of glioma cells in culture and in vivo by retrovirus transfer of the herpes simplex virus thymidine kinase gene. New Biol. 3, 608-614.
19. FICK, J., BARKER, F.G., II, DAZIN, P., WESTPHALE, E.M., BEYER, E.G., and ISRAEL, M.A. (1995). The extent of heterocellular communication mediated by gap junctions is predictive of by-stander tumor cytotoxicity in vitro. Proc. Natl. Acad. Sci. U.S.A. 92, 11071-11075.
20. FREEMAN, S.M., ABBOUD, C.N., WHARTENBY, K.A., PACKMAN, C.H., KOEPLIN, D.S., MOOLTEN, F.L., and ABRAHAM, G.N. (1993). The "bystander effect": Tumor regression when a fraction of the tumor mass is genetically modified. Cancer Res. 53, 5274-5283.
21. GOLUMBEK, P.T., HAMZEH, P.M., JAFFEE, E.M., LEVITSKY, H., LIETMAN, P.S., and PARDOLL, D.M. (1992). Herpes simplex-1 virus thymidine kinase gene is unable to completely eliminate live, nonimmunogenic tumor cell vaccines. J. Immunother. 12, 224-230.
22. HAMEL, W., MAGNELLI, L., CHIARUGI, V., and ISRAEL, M.A. (1996). Herpes simplex virus thymidine kinase/ganciclovir-mediated apoptotic death of bystander cells. Cancer Res. 56, 2697-2702.
23. HAN, Z., CHATTERJEE, D., HE, D.M., EARLY, J., PANTAZIS, P., WYCHE, J.H., and HENDRICKSON, E.A. (1995). Evidence for a G2 checkpoint in p53-independent apoptosis induction by X-irradiation. Mol. Cell. Biol. 15, 5849-5857.
24. HAUPT, Y., ROWAN, S., SHAULIAN, E., VOUSDEN, K.H., and OREN, M. (1994). Induction of apoptosis in HeLa cells by trans-activation-deficient p53. Genes Dev. 9, 2170-2183.
25. HUSCHTSCHA, L.I., BARTIER, W.A., ANDERSSON ROSS, C.E., and TATTERSALL, M.H.N. (1996). Characteristics of cancer cell death after exposure to cytotoxic drugs in vitro. Br. J. Cancer 73, 54-60.
26. IZQUIERDO, M., CORTES, M., DE FELIPE, P., MARTIN, V., DIEZGUERRA, J., TALAVERA, A., and PEREZ-HIGUERAS, A. (1995). Long-term rat survival after malignant brain tumor regression by retroviral gene therapy. Gene Ther. 2, 66-69.
27. KANEKO, Y., and TSUKAMOTO, A. (1995). Gene therapy of hepatoma: Bystander effects and non-apoptotic cell death induced by thymidine kinase and ganciclovir. Cancer Lett. 96, 105-110.
28. KIMURA, M., TAGAWA, M., TAKENAGA, K., NAKAGAWARA, A., HORITSU, K., YAMAGUCHI, T., SAISHO, H., and SAKIYAMA, S. (1997). Drug resistance to ganciclovir observed in suicide gene therapy is due to the loss of integrated herpes simplex virus-thymidine kinase gene. Int. J. Oncol. 10, 775-778.
29. KRAJEWSKI, S., KRAJEWSKA, M., EHRMANN, J., SIKORSKA, M., LACH, B., CHATTEN, J., and REED, J.C. (1997). Immunohistochemical analysis of Bcl-2, Bcl-X, Mcl-1, and Bax in tumors of central and peripheral nervous system origin. Am. J. Pathol. 150(3), 805-814.
30. KUHL, J.S., KRAJEWSKI, S., DURAN, G.E., REED, J.C., and SIKIC, B.I. (1997). Spontaneous overexpression of the long form of the Bcl-X protein in a highly resistant P388 leukemia. Br. J. Cancer 75, 268-274.
31. LANE, D.P. (1993). A death in the life of p53. Nature (London) 362, 786-787.
32. LANE, D.P. (1994). The regulation of p53 function. Int. J. Cancer 57, 623-627.
33. LEVINE, A.J. (1997). p53. the cellular gatekeeper for growth and division. Cell 88, 323-331.
34. LOUIS, D.N. (1994). The p53 gene and protein in human brain tumors. J. Neuropathol. Exp. Neurol. 53, 11-21.
35. LOWE, S.W., SCHMITT, E.M., SMITH, S.W., OSBORNE, B.A., and JACKS, T. (1993). p53 is required for radiation-induced apoptosis in mouse thymocytes. Nature (London) 362, 847-849.
36. MINN, A.J., RUDIN, C.H., BOISE, L.H., and THOMPSON, C.B. (1995). Expression of Bcl-xL can confer a multidrug resistance phenotype. Blood 86(5), 1903-1910.
37. MIYASHITA, T., and REED, J.C. (1995). Tumor suppressor p53 is a direct transcriptional activator of the human bax gene. Cell 80, 293-299.
38. MOOLTEN, F.L. (1986). Tumor chemosensitivity conferred by inserted herpes thymidine kinase genes: Paradigm for a prospective cancer control strategy. Cancer Res. 46, 5276-5281.
39. MOOLTEN, F.L. (1994). Drug sensitivity (suicide) genes for selective cancer chemotherapy. Cancer Gene Ther. 1, 279-287.
40. NAGANE, M., COUFAL, F., LIN, H., BOGLER, O., CAVENEE, W.K., and HUANG, H.-J.S. (1997). A common mutant epidermal growth factor receptor confers enhanced tumorigenicity on human glioblastoma cells by increasing proliferation and reducing apoptosis. Cancer Res. 56, 5079-5086.
41. OLDFIELD, E.H., RAM, Z., CULVER, K.W., BLAESE, R.M., DEVROOM, H.L., and ANDERSON, W.F. (1993). Gene therapy for the treatment of brain tumors using intratumoral transduction with the thymidine kinase gene and intravenous ganciclovir. Hum. Gene Ther. 4, 39-69.
42. ONO, Y., TAMIYA, T., ICHIKAWA, T., MATSUMOTO, K., FURATA, T., OHMOTO, T., AKIMYAMA, K., SEKI, S., UEKI, K., and LOUIS, D.N. (1997). Accumulation of wild-type p53 in astrocytomas is associated with increased p21 expression. Acta Neuropathol. 94, 21-27.
43. OSAKI, T., TANIO, Y., TACHIBANA, I., HOSOE, S., KUMAGAI, T., KAWASE, I., OIKAWA, S., and KISHIMOTO, T. (1994). Gene therapy for carcinoembryonic antigen-producing lung cancer cells by cell type-specific expression of herpes simplex thymidine kinase gene. Cancer Res. 54, 5258-5261.
44. RAM, Z., CULVER, K.W., WALLBRIDGE, S., ISHII, S., OLDFIELD, E.H., and BLAESE, R.M. (1993). In situ retroviral-mediated gene transfer for the treatment of brain tumors in rat. Cancer Res. 53, 83-88.
45. ROWAN, S., LUDWIG, R.L., HAUPT, Y., BATES, S., LU, X., OREN, M., and VOUSDEN, K.H. (1996). Specific loss of apoptotic but not cell-cycle function in a human tumor derived p53 mutant. EMBO J. 15(4), 827-838.
46. SAMEJIMA, Y., and MURUELO, D. (1995). Bystander killing induces apoptosis and is inhibited by forskolin. Gene Ther. 2, 50-58.
47. SCOTTO, C., DELOULME, J.C., ROUSSEAU, D., CHAMBAZ, E., and BAUDIER, J. (1998). Calcium and S100B regulation of p53-dependent cell growth arrest and apoptosis. Mol. Cell. Biol. 18(7), 4272-7281.
48. L. J. Biol. Chem. 371(37), 22764-22772.
49. SIMONIAN, P.L., GRILLOT, D.A.M., and NUNEZ, G. (1997). Bcl-2 and Bcl-xL can differentially block chemotherapy-induced cell death. Blood 90(3), 1208-1216.
50. STURTZ, G.F., WADELL, K., SHULOCK, J., CHEN, X., CARUSO, M., SANSON, M., SNODGRASS, H.R., and PLATIKA, D. (1997). Variable efficiency of the thymidine kinase/ganciclovir system in human glioblastoma cell lines: Implications for gene therapy. Hum. Gene Ther. 8, 1945-1953.
51. TAKAMIYA, Y., SHORT, M.P., EZZEDINE, Z.D., MOOLTEN, F.L., BREAKEFIELD, X.O., and MARTUZA, R.L. (1992). Gene therapy of malignant brain tumors: A rat glioma line bearing the herpes simplex virus type 1-thymidine kinase gene and wild type retrovirus kills other tumor cells. J. Neurosoci. Res. 33, 493-503.
52. VILE, R.G., CASTLEDEN, S., MARSHALL, J., CAMPLEJOHN, R., UPTON, C., and CHONG, H. (1997). Generation of an anti-tumour immune response in a nonimmunogenic tumour: HSV-tk killing in vivo stimulates a mononuclear infiltrate and a Th1-like profile of intratumoural cytokine expression. Int. J. Cancer 71, 267-274.
53. VRIONIS, F.D., WU, J.K., QI, P., CANO, W.G., and CHERINGTON, V. (1996). Tumor cells expressing the herpes simplex virus-thymidine kinase gene in the treatment of Walker 256 meningeal neoplasia in rats. J. Neurosurg. 84, 250-257.
54. WAGNER, A.J., KOKONTIS, J.M., and HAY, N. (1994). Myc-mediated apoptosis requires wild-type p53 in a manner independent of cell cycle arrest and the ability of p53 to induce p21 WAF/CIP1. Genes Dev. 8, 2817-2830.
55. WALLACE, H., CLARKE, A.R., HARRISON, D.J., HOOPER, M.L., and BISHOP, J.O. (1996). Ganciclovir-induced ablation of non-proliferating thyrocytes expressing herpesvirus thymidine kinase occurs by p53-independent apoptosis. Oncogene 13, 55-61.